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A method is described for the elimination of non-specific leavage of fusion proteins by factor Xa. putative non-specific leavage sites C-terminal 
to lysyl residues are blocked by reversible acylation by 3,4,5,6-tetrahydrophthalic nhydride prior to cleavage. After cleavage, the acyl groups are 
removed quantitatively by exposure to slightly acidic conditions. This method employs no harsh reagents or conditions, and may be generally applic- 
able to factor Xa cleavage of fusion proteins. 
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1. INTRODUCTION 
Efficient production of specific proteins by recombi- 
nant DNA techniques often requires expression of a fu- 
sion protein. To release the desired protein, the fusion 
protein must be cleaved at a specific site, which cannot 
also occur within any of the proteins to be made. 
Specific proteases can be used for this purpose. 
be achieved under gentle conditions [8,9]; this is 
therefore a method of ~tentially general use for the 
protection of fusion proteins from non-specific 
cleavage after lysyl residues by factor Xa. 
2. EXPERIMENTAL 
2.1. Construction of pLcIIFX-porcine tnyoglobin mutants 
The expression vector pLcIIFX created by Nagai and 
Thogersen [1,2] contains, at the junction between the 
partial ~11 sequence and the site of the sequence of the 
protein to be expressed, a sequence encoding the 
tetrapeptide r~ognition sequence of blood coagulation 
factor Xa for prothrombin (Ile-Glu-Gly-~g) [3]. Fac- 
tor Xa cleaves the fusion protein (CIIFX-protein) at the 
C-terminal side of the tetrapeptide sequence, liberating 
authentic recombinant protein [I]. This expression 
system has been used for the production of several 
eukaryotic proteins in E. coli [2,4], including globins 
[5-71. 
Porcine myoglobin was expressed from the Ml3mpl8FXpmyo 
template [7]. Most of the studies were carried out on a mutant form 
(P37Y), in which the template was altered by site-directed 
mutagenesis [lo,1 11. Mutant clones were identified by sequencing 
along their entire length [12]. The 6#-bp ~u~HI/~~~dIII digest 
fragment was ligated into pLcII 121. The ligation mixture was 
transfectecl into E. cufi QY 13; clones were setected by small-scale pro- 
tein induction assay [2]. 
2.2. Induction, expression and purification of mutant fusion protein 
Protein synthesis and inclusion body preparation were according to 
Factor Xa has been observed to cleave at additional 
sites other than the tetrapeptide recognition sequence in 
some fusion proteins [2,5], including wild type and mu- 
tant CIIFX-porcine myoglobin (pMb) used in this 
study. Non-specific cleavage of the pMb fusion protein 
is shown here to be due to factor Xa, to be likely to oc- 
cur at lysyl residues, and to be inhibited by the reversi- 
ble acylation of the fusion protein amino groups by 
THPA. Both acylation by THPA and deacylation may 
Nagai and Thegersen [2]. The fusion protein was solubilized in urea- 
PED (8 M urea, 50 mM sodium phosphate (pH 8.0), 1 mM EDTA, 
1 mM DTT), clarified by centrifugation and purified by gel filtration 
on a Sephacryl S-200 column pre-equillbratecl with urea-PED. The 
concentrations of fusion protein samples were determined from their 
absorbance at 280 nm in 6 M guanidinlum chloride, 20 mM sodium 
phosphate (pH 6.5), using extinction coefficients derived from the 
tryptophan and tyrosine content 1131 (ezse = 13.9 mM-‘*cm-‘). 
2.3. THPA ucyiation of mutant fusion protein 
THPA acylation was achieved according to Gibbons and 
Schachman [8,9]. THPA (0.5 M in acetone) was added, with stirring, 
to the fusion protein sample at 4°C. If necessary, 0.5 M NaOH was 
added dropwise to maintain a pH of 8-8.5. After 30 min, the sample 
was dialyzed exhaustively against 50 mM Tris-HCl (pH 8.0), 0.5 M 
urea, 1 mM CaC12 at 4’C. 
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2.4. Preparation of protease inhibitor-treated factor Xa 
Separate 15 ~1 fractions, each containing 9 pg factor Xa, were in- 
cubated with one of the following protease inhibitors prior to inclu- 
sion in a fusion protein cleavage reaction: 
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(i) 5 U hirndin (type H7380, 500 Wmg, Sigma Chemical), at final 
reaction conditions of 50 mM Tris-WCI @W 7.4), for 15 min at 37°C 
[14,1S]. The degree of contaminant bdellin (trypsin-plasmin in- 
hibitor) activity [16] in the hirudin preparation was determined by 
assaying the activity of trypsin solutions, according to Kassell [17], 
after preincubation with the hirudin preparation for 15 min at 37°C 
in 0.2 M triethanolamine @H 7.8), 10 mM Cat&. Comparison with 
&itration curves of trypsin inhibitor activity for pure bdellins 1181 per- 
mitted estimation of the bdellin content of the hirudin preparation. 
(ii) 12.5 nmo1 E-64 (Siia Chemical), prepared in 101 D_MSU, 
0.1% T&on X-f@ for 15 min at 2SY [t9], 
(iii> 5 U bovine anti-~rornb~n III (Sigma Chemical), at final reac- 
tion conditions of 0.1 M NaCI, 0.1 M Tris-NCi (pH 8.31, for t5 min 
at 3?*C [ZO]. 
(iv) 30 pg BPTI (Bayer AG), at final reaction conditions of 67 mM 
sodium phosphate (pH 8.0), for IS mln at 25°C [21,22]. 
2.5. Ueavage of fusion protein with factivr Xa 
Non-THPA acylated CIIFXgMb fusion proteins are only partially 
soluble at 0.45 mg/ml after dialysis against 50 mM Tris-HCl (PH 
8,0), 0.5 M urea, 1 mM CaC12, whereas TWA acylated fusion pro- 
teins are fully soluble after dialysis. Cleavage with factor Xa was per- 
formed at 28°C at an enzyme to substrate ratio of 1. :80 (w/w). 
Dialysis for W-40 h at 4°C and pH 6 is a general method for the 
quantitative removal of THP groups from modified proteins f&9]. 
pMb precipitates under these conditions, however, as this pH is close 
to the pZ of the protein, and quantitative deacylation was not observ- 
ed. Quantitative removal of THP groups from pMb can be produced 
using conditions where the protein remains soluble, such as dialysis 
against 0.1 M acetic acid for 20 h, or addition of guanidinium 
chloride to 5 M and incubation at 4OC for 20 h. 
2.7. Purification of porcine myoglabin 
If the removal of acylating groups by dialysis was not quantitative, 
the deacylated species was purified by anion exchange 
chromatography on a DEAE-Sepharose CUB column (40 cm x 
1 cm diameter), ~ui~~brat~ with 4.S M urea, 25 mM Tris-HCf (pH 
7.6). The sample was Ioaded in the same buffer, and eluted with a 
200 mf linear gradient of O-O.1 M NaCl. 
2.8. Etectrophoretic analysis 
%Impks from cleavage reactions were analyzed by SDS- 
polyacrylamide gel electrophoresis, according to Schaegger and Von 
Jagow [23]. A 16.5% T, 3% C separating gel was used in all in- 
stances, with a 10% T, 3% C spacer gel. 
The degree of THPA acylation of samples was determined by 
polyacrylamide gel electrophoresis [24], with 8 M urea included in gel 
mixtures and samples 181. 
3. RESULTS AND DISCUSSIOI’3 
Cleavage of ~~mod~~ed CIIFX-pMb (P37Y) with 
factor Xa generates several protein species by non- 
specific cieavage, in addition to authentic myoglobin 
(Fig. la), The rate of non-specific cleavage is not af- 
fected significantly by E-64 (Fig. lb), a specific in- 
hibitar of cysteine proteases, or by hirudin (Fig. lc), a 
specific inhibitor of thrombin. The hirudin preparation 
was found to contain bdellins at 25-30% by weight (a 
level comparable to those reported for other crude 
preparations [16]), therefore non-specific cleavage is 
not due to plasmin activity. However, both anti- 
thrombin III (a specific inhibitor of thrombin and fac- 
tor Xa), and BPTI (a general inhibitor of serine pro- 
teases) inhibit all cleavage (Fig. Id, e). It is Iikely, 
therefore, that non-specific cleavage is due to factor 
Xa, not to proteases present as contaminants. 
The degree of non-specific cleavage varies between 
wild type and mutant myoglobin species, with mutant 
CIIFX-pMb (P37Y) the most susceptible, This implies 
a dependence of cleavage not only on primary se- 
quence, but also on conformation and accessibility. 
The molecular weights of the non-specific cleavage pro- 
ducts were determined by ~~~-polyacryl~ide gel efec- 
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Fig. 1. SDS-PAGE of species generated by cleavage of unmodified CIIFX-pMb (P37Y) by protease inhibitor-treated factor Xa. The inhibitors 
used, and their concentration per 9pg aliquot of factor Xa were: {a) no treatment; (h) 12.5 nmol E-64; (c) 0.5 U hirudin; (d) 0.5 U anti-thrombin 
III; (e) JO peg BPTI. The molecular weights of cleavage products are given in Table I. Treatments a, b, c and treatments d, e were run on different 
gels; in each case, the upper arrowhead identifies the fusion protein (approx. mol. wt. 2iZOO IrDaj and the lower arrow identifies pMb (P37Yj 
(approx. mol. wt. 17400 kDa). 
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Table 1 
Major cleavage products generated on digestion of unmodified 
CIIFX-pMb (P37Y) by factor Xa 
Polypeptide 
molecular weighta 
21380 + 200b 
20230 + 320 
18790 + 310 
17700 i 2W 
15740 f 290 
15170 f 70 
Putative cleavage site at the 
peptide bond C-terminal to: 
None 
Lys145 (or Arg139) 
Lys133 
FXa cleavage site 
FXa cleavage site and Lys145 (or Arg139) 
Lys96 or Lys98 
a Error limits are the standard deviation in molecular weight (n = 5) 
b CIIFX-pMb (P37Y) fusion protein 
’ Authentic pMb (P37Y) 
trophoresis. Putative cleavage sites were identified 
from the calculated molecular weights (Table I), which 
suggested that cleavage was occurring at lysyl residues. 
The primary sequences of pMb [25,26] and /-globin 
[27,28] were compared to identify a possible basis for 
the non-specific cleavage that occurs with the former, 
but not the latter. There is a significant difference bet- 
ween fi-globin and pMb in the number of lysyl residues 
they contain (11 and 19, respectively), and in their 
distribution throughout the protein. In pMb, 4 regions 
may be identified in which clustering of lysyl residues 
occurs, giving sequences with multiple positive charge. 
Only one such region occurs in fl-globin, suggesting 
that factor Xa was cleaving at sites 
charge. 
of high positive 
a b c d e 
Net change 
of charge 
of pMb (P37Y) 
Fig. 2. Comparison of the degree of deacylation achieved by dialysis 
against 0.1 M acetic acid and dialysis against 50 mM citrate buffer 
@H 5.8), by urea-PAGE of dialysates: (a) unmodified fusion protein 
CIIFX-pMb (P37Y); (b) THP acylated fusion protein; (c) acylated 
pMb (P37Y) generated by factor Xa cleavage; (d) acylated pMb 
(P37Y) after dialysis against 50 mM citrate buffer @H 5.8) for 20 h 
at 4’C; (e) acylated pMb (P37Y) after dialysis against 0.1 M acetic 
acid for 20 h at 4°C. 
The possibility that non-specific cleavage was occurr- 
ing at lysyl residues led to attempts to minimize it by 
reversible acylation of the fusion protein. The most 
readily reversible acylation reagent is THPA [8]. Acyla- 
tion of the CIIFX-pMb species with THPA leads to a 
change of net charge of -2 for each amino group 
acylated [8]. Electrophoretic analysis of acylated 
samples demonstrated primarily the expected species, 
but also some with changes of net charge of -3, -5, 
etc. The presence of fusion protein with a change of net 
charge of - 1, prior to blocking (Fig. 2a), indicates that 
another covalent modification, such as spontaneous 
deamidation [29] or carbamylation by cyanate on the 
degradation of urea [30], occurs in addition to any 
possible acylation by contaminants of the commercial 
THPA preparation and is at least partly responsible for 
the generation of these species. The minor species are 
separated from unmodified pMb by anion exchange 
chromatography. 
A stoichiometry of 0.8 THPA molecules per free 
amino group was empirically determined to be suffi- 
cient to eliminate non-specific cleavage (Fig. 3). The 
observation that THP acylation with a stoichiometry of 
less than 1 is sufficient to suppress cleavage is unlikely 
to be applicable to all proteins. Native pMb contains 4 
clusters of lysyl residues; it is possible that either THP 
acylation of all lysyl a-amines in such clusters is 
sterically unfavored, or that partial acylation of each 
cluster is sufficient to eliminate potential cleavage 
within that region. 
Generally, THP groups can be removed very easily, 
without the need for harsh reagents or conditions [8,9], 
which makes this method preferable to 
trifluoroacetylation [3 l] or acylation by citraconic 
anhydride [32] for masking amino groups. However, 
dialysis at pH 5.8-6.0 leads to precipitation of pMb 
and pMb (P37Y), and non-denaturing polyacrylamide 
gel electrophoresis of the dialysate in the presence of 
Time of incubation of THP-acylated 
CIIfX-pMb (P37Y) with factorxa (hours) 
0 0.5 1 3 7 
M~l$lgr(gii~ 
16.95 - 
14.40 - 
4 Fusion protein 
4 pMb (P37Y) 
10.67 - 
Fig. 3. SDS-PAGE of the products of cleavage of THP acylated 
CIIFX-pMb (P37Y) (0.8 THPA molecules per free amino group) by 
factor Xa. 
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urea shows that deacylation is not quantitative 
(Fig. 2d). Quantitative deacylation of the pMb species 
therefore requires different conditions from those 
generally applicable to other proteins, and was achiev- 
ed by either dialyzing against 0.1 M acetic acid, or by 
incubating in 5 M guanidinium chloride at 4°C and pH 
5.8-6.0 (Fig. 2e). After removal of minor charged 
species by anion exchange chromatography, the yield 
of pMb (P37Y) from deblocking by either acetic acid or 
guanidi~um chloride incubation is typically 0.70 mglg 
packed cells (wet weight). This compares favorably 
with 0.18 mg/g yielded by partial cleavage of non- 
acylated CIIFX-pMb (P37Y) (Fig. la), if fully quan- 
titative separation of cleavage products is achieved. 
Acylation by THPA may be suitable as a general 
method for eliminating non-specific cleavage of 
CIIFX-fusion proteins by factor Xa. Where the pl of 
the fusion protein is less than 8 (the pH at which factor 
Xa cleavage is routinely executed), the change in net 
charge on acylation by THPA may also increase the 
solubility of the fusion protein, accelerating the rate of 
cleavage. 
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